OptiNose Inc (NASDAQ:OPTN) insider Thomas Edward Gibbs bought 2,000 shares of the stock in a transaction dated Wednesday, August 15th. The stock was purchased at an average cost of $12.69 per share, for a total transaction of $25,380.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Shares of NASDAQ OPTN traded down $0.38 during midday trading on Friday, hitting $13.80. The company had a trading volume of 406,684 shares, compared to its average volume of 193,275. The company has a quick ratio of 9.50, a current ratio of 9.66 and a debt-to-equity ratio of 0.57. OptiNose Inc has a twelve month low of $12.51 and a twelve month high of $30.00. The stock has a market capitalization of $797.38 million and a price-to-earnings ratio of -2.45.

OptiNose (NASDAQ:OPTN) last announced its quarterly earnings data on Tuesday, August 14th. The company reported ($0.64) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.77) by $0.13. The company had revenue of $1.27 million during the quarter, compared to analyst estimates of $1.01 million. equities research analysts expect that OptiNose Inc will post -3.15 EPS for the current fiscal year.

Several brokerages have recently weighed in on OPTN. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $34.00 target price on shares of OptiNose in a report on Wednesday, July 18th. Zacks Investment Research cut shares of OptiNose from a “buy” rating to a “hold” rating in a research note on Wednesday. Cantor Fitzgerald set a $30.00 price objective on shares of OptiNose and gave the company a “buy” rating in a research note on Tuesday. Finally, ValuEngine upgraded shares of OptiNose from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $29.67.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Waddell & Reed Financial Inc. lifted its stake in shares of OptiNose by 128.2% in the second quarter. Waddell & Reed Financial Inc. now owns 735,140 shares of the company’s stock valued at $20,569,000 after purchasing an additional 412,950 shares during the period. Bank of America Corp DE lifted its stake in shares of OptiNose by 46.7% in the second quarter. Bank of America Corp DE now owns 34,900 shares of the company’s stock valued at $976,000 after purchasing an additional 11,109 shares during the period. Summit Trail Advisors LLC acquired a new stake in shares of OptiNose in the second quarter valued at about $109,000. FMR LLC raised its position in OptiNose by 7.7% during the second quarter. FMR LLC now owns 6,117,208 shares of the company’s stock worth $171,160,000 after acquiring an additional 437,747 shares during the last quarter. Finally, BlackRock Inc. raised its position in OptiNose by 336.0% during the second quarter. BlackRock Inc. now owns 997,257 shares of the company’s stock worth $27,903,000 after acquiring an additional 768,521 shares during the last quarter. Hedge funds and other institutional investors own 31.20% of the company’s stock.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Read More: How to Use the New Google Finance Tool

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.